Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Ion-selective electrodes.

Analytical chemistry

Solsky RL.
PMID: 20527837
Anal Chem. 1990 Jun;62(12):21R-33R. doi: 10.1021/ac00211a011.

No abstract available.

Cite
Solsky RL. Ion-selective electrodes. Anal Chem. 1990;62(12):21R-33Rdoi: 10.1021/ac00211a011.
Solsky, R. L. (1990). Ion-selective electrodes. Analytical chemistry, 62(12), 21R-33R. https://doi.org/10.1021/ac00211a011
Solsky, R L. "Ion-selective electrodes." Analytical chemistry vol. 62,12 (1990): 21R-33R. doi: https://doi.org/10.1021/ac00211a011
Solsky RL. Ion-selective electrodes. Anal Chem. 1990 Jun;62(12):21R-33R. doi: 10.1021/ac00211a011. PMID: 20527837.
Copy Download .nbib Format: NLM
Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017.

Journal of the American Academy of Dermatology

Cheraghlou S, Watsky KL, Cohen JM.
PMID: 32387633
J Am Acad Dermatol. 2021 Nov;85(5):1218-1226. doi: 10.1016/j.jaad.2020.04.163. Epub 2020 May 05.

BACKGROUND: Patch testing is the best diagnostic test for allergic contact dermatitis. However, there is presently a lack of data on the test's geographic availability and the characteristics of the providers offering this test across the United States.OBJECTIVE: To...

Cite
Cheraghlou S, Watsky KL, Cohen JM. Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017. J Am Acad Dermatol. 2020;85(5):1218-1226doi: 10.1016/j.jaad.2020.04.163.
Cheraghlou, S., Watsky, K. L., & Cohen, J. M. (2021). Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017. Journal of the American Academy of Dermatology, 85(5), 1218-1226. https://doi.org/10.1016/j.jaad.2020.04.163
Cheraghlou, Shayan, et al. "Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017." Journal of the American Academy of Dermatology vol. 85,5 (2021): 1218-1226. doi: https://doi.org/10.1016/j.jaad.2020.04.163
Cheraghlou S, Watsky KL, Cohen JM. Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017. J Am Acad Dermatol. 2021 Nov;85(5):1218-1226. doi: 10.1016/j.jaad.2020.04.163. Epub 2020 May 05. PMID: 32387633.
Copy Download .nbib Format: NLM
Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data.

Current oncology (Toronto, Ont.)

Walsh RL, Lofters A, Moineddin R, Krzyzanowska M, Grunfeld E.
PMID: 34898582
Curr Oncol. 2021 Nov 17;28(6):4786-4804. doi: 10.3390/curroncol28060405.

(1) Background: Wait times to chemotherapy are associated with morbidity and mortality in breast cancer patients; however, it is unclear how primary care physician (PCP) continuity impacts these wait times, or whether this association is different in immigrants, who...

Cite
Walsh RL, Lofters A, Moineddin R, et al. Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data. Curr Oncol. 2021;28(6):4786-4804doi: 10.3390/curroncol28060405.
Walsh, R. L., Lofters, A., Moineddin, R., Krzyzanowska, M., & Grunfeld, E. (2021). Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data. Current oncology (Toronto, Ont.), 28(6), 4786-4804. https://doi.org/10.3390/curroncol28060405
Walsh, Rachel Lin, et al. "Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data." Current oncology (Toronto, Ont.) vol. 28,6 (2021): 4786-4804. doi: https://doi.org/10.3390/curroncol28060405
Walsh RL, Lofters A, Moineddin R, Krzyzanowska M, Grunfeld E. Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data. Curr Oncol. 2021 Nov 17;28(6):4786-4804. doi: 10.3390/curroncol28060405. PMID: 34898582; PMCID: PMC8628668.
Copy Download .nbib Format: NLM
Complex Repair of a Completely Fused Nullicuspid Aortic Valve Late in Adolescence.

World journal for pediatric & congenital heart surgery

Meza JM, Nellis JR, Rankin JS, Wolsky RM, Badhwar V, Hughes GC, Turek JW.
PMID: 34353178
World J Pediatr Congenit Heart Surg. 2021 Nov;12(6):790-793. doi: 10.1177/21501351211017854. Epub 2021 Aug 05.

We report a case of an 18-year-old female who presented with severe aortic stenosis and insufficiency, eight years following resection of a subaortic membrane. On echocardiography, she was found to have a completely fused or nullicuspid valve, with three...

Cite
Meza JM, Nellis JR, Rankin JS, et al. Complex Repair of a Completely Fused Nullicuspid Aortic Valve Late in Adolescence. World J Pediatr Congenit Heart Surg. 2021;12(6):790-793doi: 10.1177/21501351211017854.
Meza, J. M., Nellis, J. R., Rankin, J. S., Wolsky, R. M., Badhwar, V., Hughes, G. C., & Turek, J. W. (2021). Complex Repair of a Completely Fused Nullicuspid Aortic Valve Late in Adolescence. World journal for pediatric & congenital heart surgery, 12(6), 790-793. https://doi.org/10.1177/21501351211017854
Meza, James M, et al. "Complex Repair of a Completely Fused Nullicuspid Aortic Valve Late in Adolescence." World journal for pediatric & congenital heart surgery vol. 12,6 (2021): 790-793. doi: https://doi.org/10.1177/21501351211017854
Meza JM, Nellis JR, Rankin JS, Wolsky RM, Badhwar V, Hughes GC, Turek JW. Complex Repair of a Completely Fused Nullicuspid Aortic Valve Late in Adolescence. World J Pediatr Congenit Heart Surg. 2021 Nov;12(6):790-793. doi: 10.1177/21501351211017854. Epub 2021 Aug 05. PMID: 34353178.
Copy Download .nbib Format: NLM
Can we safely forgo hysterectomy in non-fertility-sparing surgery for borderline ovarian tumors?.

Gynecologic oncology reports

Hill BL, Moroney MR, Post MD, Sawyer B, Sheeder J, Wolsky RJ, Lefkowits C.
PMID: 33665295
Gynecol Oncol Rep. 2021 Feb 12;36:100730. doi: 10.1016/j.gore.2021.100730. eCollection 2021 May.

Forgoing hysterectomy as part of borderline ovarian tumor (BOT) staging is considered appropriate for fertility preservation. We evaluated whether forgoing hysterectomy may also be acceptable in non-fertility-sparing surgery by evaluating the frequency of uterine involvement and the rate of...

Cite
Hill BL, Moroney MR, Post MD, et al. Can we safely forgo hysterectomy in non-fertility-sparing surgery for borderline ovarian tumors?. Gynecol Oncol Rep. 2021;36:100730doi: 10.1016/j.gore.2021.100730.
Hill, B. L., Moroney, M. R., Post, M. D., Sawyer, B., Sheeder, J., Wolsky, R. J., & Lefkowits, C. (2021). Can we safely forgo hysterectomy in non-fertility-sparing surgery for borderline ovarian tumors?. Gynecologic oncology reports, 36100730. https://doi.org/10.1016/j.gore.2021.100730
Hill, Breana L, et al. "Can we safely forgo hysterectomy in non-fertility-sparing surgery for borderline ovarian tumors?." Gynecologic oncology reports vol. 36 (2021): 100730. doi: https://doi.org/10.1016/j.gore.2021.100730
Hill BL, Moroney MR, Post MD, Sawyer B, Sheeder J, Wolsky RJ, Lefkowits C. Can we safely forgo hysterectomy in non-fertility-sparing surgery for borderline ovarian tumors?. Gynecol Oncol Rep. 2021 Feb 12;36:100730. doi: 10.1016/j.gore.2021.100730. eCollection 2021 May. PMID: 33665295; PMCID: PMC7900677.
Copy Download .nbib Format: NLM
Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs.

Pathogens (Basel, Switzerland)

Diggins NL, Skalsky RL, Hancock MH.
PMID: 33668486
Pathogens. 2021 Feb 13;10(2). doi: 10.3390/pathogens10020200.

Human cytomegalovirus (HCMV) encodes 22 mature microRNAs (miRNAs), which regulate a myriad of cellular processes, including vesicular trafficking, cell cycle progression, apoptosis, and immune evasion, as well as viral gene expression. Recent evidence points to a critical role for...

Cite
Diggins NL, Skalsky RL, Hancock MH. Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs. Pathogens. 2021;10(2)doi: 10.3390/pathogens10020200.
Diggins, N. L., Skalsky, R. L., & Hancock, M. H. (2021). Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs. Pathogens (Basel, Switzerland), 10(2), . https://doi.org/10.3390/pathogens10020200
Diggins, Nicole L, et al. "Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs." Pathogens (Basel, Switzerland) vol. 10,2 (2021). doi: https://doi.org/10.3390/pathogens10020200
Diggins NL, Skalsky RL, Hancock MH. Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs. Pathogens. 2021 Feb 13;10(2). doi: 10.3390/pathogens10020200. PMID: 33668486; PMCID: PMC7918750.
Copy Download .nbib Format: NLM
Reengineering Critical Laboratory Testing for Timely Chemotherapeutic Management.

The journal of applied laboratory medicine

Yi X, Leung EKY, Mika D, Wolsky RJ, Van Slambrouck C, Leanse J, Nabhan C, Yeo KJ.
PMID: 33636941
J Appl Lab Med. 2018 Sep 01;3(2):240-249. doi: 10.1373/jalm.2017.025973.

BACKGROUND: Delivery of cytotoxic therapy is a complex multifaceted process that involves harmonized collaboration between all systems involved. Optimizing laboratory turnaround time (TAT) ensures timely delivery of chemotherapy, which potentially translates into improved patient outcomes and satisfaction. In this...

Cite
Yi X, Leung EKY, Mika D, et al. Reengineering Critical Laboratory Testing for Timely Chemotherapeutic Management. J Appl Lab Med. 2018;3(2):240-249doi: 10.1373/jalm.2017.025973.
Yi, X., Leung, E. K. Y., Mika, D., Wolsky, R. J., Van Slambrouck, C., Leanse, J., Nabhan, C., & Yeo, K. J. (2018). Reengineering Critical Laboratory Testing for Timely Chemotherapeutic Management. The journal of applied laboratory medicine, 3(2), 240-249. https://doi.org/10.1373/jalm.2017.025973
Yi, Xin, et al. "Reengineering Critical Laboratory Testing for Timely Chemotherapeutic Management." The journal of applied laboratory medicine vol. 3,2 (2018): 240-249. doi: https://doi.org/10.1373/jalm.2017.025973
Yi X, Leung EKY, Mika D, Wolsky RJ, Van Slambrouck C, Leanse J, Nabhan C, Yeo KJ. Reengineering Critical Laboratory Testing for Timely Chemotherapeutic Management. J Appl Lab Med. 2018 Sep 01;3(2):240-249. doi: 10.1373/jalm.2017.025973. PMID: 33636941.
Copy Download .nbib Format: NLM
Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data.

Current oncology (Toronto, Ont.)

Walsh RL, Lofters A, Moineddin R, Krzyzanowska M, Grunfeld E.
PMID: 34898582
Curr Oncol. 2021 Nov 17;28(6):4786-4804. doi: 10.3390/curroncol28060405.

(1) Background: Wait times to chemotherapy are associated with morbidity and mortality in breast cancer patients; however, it is unclear how primary care physician (PCP) continuity impacts these wait times, or whether this association is different in immigrants, who...

Cite
Walsh RL, Lofters A, Moineddin R, et al. Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data. Curr Oncol. 2021;28(6):4786-4804doi: 10.3390/curroncol28060405.
Walsh, R. L., Lofters, A., Moineddin, R., Krzyzanowska, M., & Grunfeld, E. (2021). Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data. Current oncology (Toronto, Ont.), 28(6), 4786-4804. https://doi.org/10.3390/curroncol28060405
Walsh, Rachel Lin, et al. "Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data." Current oncology (Toronto, Ont.) vol. 28,6 (2021): 4786-4804. doi: https://doi.org/10.3390/curroncol28060405
Walsh RL, Lofters A, Moineddin R, Krzyzanowska M, Grunfeld E. Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data. Curr Oncol. 2021 Nov 17;28(6):4786-4804. doi: 10.3390/curroncol28060405. PMID: 34898582.
Copy Download .nbib Format: NLM
Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017.

Journal of the American Academy of Dermatology

Cheraghlou S, Watsky KL, Cohen JM.
PMID: 32387633
J Am Acad Dermatol. 2021 Nov;85(5):1218-1226. doi: 10.1016/j.jaad.2020.04.163. Epub 2020 May 05.

BACKGROUND: Patch testing is the best diagnostic test for allergic contact dermatitis. However, there is presently a lack of data on the test's geographic availability and the characteristics of the providers offering this test across the United States.OBJECTIVE: To...

Cite
Cheraghlou S, Watsky KL, Cohen JM. Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017. J Am Acad Dermatol. 2020;85(5):1218-1226doi: 10.1016/j.jaad.2020.04.163.
Cheraghlou, S., Watsky, K. L., & Cohen, J. M. (2021). Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017. Journal of the American Academy of Dermatology, 85(5), 1218-1226. https://doi.org/10.1016/j.jaad.2020.04.163
Cheraghlou, Shayan, et al. "Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017." Journal of the American Academy of Dermatology vol. 85,5 (2021): 1218-1226. doi: https://doi.org/10.1016/j.jaad.2020.04.163
Cheraghlou S, Watsky KL, Cohen JM. Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017. J Am Acad Dermatol. 2021 Nov;85(5):1218-1226. doi: 10.1016/j.jaad.2020.04.163. Epub 2020 May 05. PMID: 32387633.
Copy Download .nbib Format: NLM
Infectious disbelief.

Canadian Medical Association journal

Walley RL.
PMID: 20313040
Can Med Assoc J. 1978 Nov 18;119(10):1164.

No abstract available.

Cite
Walley RL. Infectious disbelief. Can Med Assoc J. 1978;119(10):1164
Walley, R. L. (1978). Infectious disbelief. Canadian Medical Association journal, 119(10), 1164.
Walley, R L. "Infectious disbelief." Canadian Medical Association journal vol. 119,10 (1978): 1164.
Walley RL. Infectious disbelief. Can Med Assoc J. 1978 Nov 18;119(10):1164. PMID: 20313040; PMCID: PMC1818539.
Copy Download .nbib Format: NLM
Utilization and Geographic Variation of Patch Testing Among Medicare Beneficiaries.

Dermatitis : contact, atopic, occupational, drug

Meyer MD, McDonald H, Lott J, Watsky KL.
PMID: 27427825
Dermatitis. 2016 Jul-Aug;27(4):234-6. doi: 10.1097/DER.0000000000000190.

No abstract available.

Cite
Meyer MD, McDonald H, Lott J, et al. Utilization and Geographic Variation of Patch Testing Among Medicare Beneficiaries. Dermatitis. 2016;27(4):234-6doi: 10.1097/DER.0000000000000190.
Meyer, M. D., McDonald, H., Lott, J., & Watsky, K. L. (2016). Utilization and Geographic Variation of Patch Testing Among Medicare Beneficiaries. Dermatitis : contact, atopic, occupational, drug, 27(4), 234-6. https://doi.org/10.1097/DER.0000000000000190
Meyer, M David, et al. "Utilization and Geographic Variation of Patch Testing Among Medicare Beneficiaries." Dermatitis : contact, atopic, occupational, drug vol. 27,4 (2016): 234-6. doi: https://doi.org/10.1097/DER.0000000000000190
Meyer MD, McDonald H, Lott J, Watsky KL. Utilization and Geographic Variation of Patch Testing Among Medicare Beneficiaries. Dermatitis. 2016 Jul-Aug;27(4):234-6. doi: 10.1097/DER.0000000000000190. PMID: 27427825.
Copy Download .nbib Format: NLM
The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval.

Clinical cancer research : an official journal of the American Association for Cancer Research

Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG.
PMID: 32928797
Clin Cancer Res. 2020 Dec 01;26(23):6362-6373. doi: 10.1158/1078-0432.CCR-20-1762. Epub 2020 Sep 14.

PURPOSE: Ovarian cancer has one of the highest deaths to incidence ratios across all cancers. Initial chemotherapy is effective, but most patients develop chemoresistant disease. Mechanisms driving clinical chemo-response or -resistance are not well-understood. However, achieving optimal surgical cytoreduction...

Cite
Jordan KR, Sikora MJ, Slansky JE, et al. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020;26(23):6362-6373doi: 10.1158/1078-0432.CCR-20-1762.
Jordan, K. R., Sikora, M. J., Slansky, J. E., Minic, A., Richer, J. K., Moroney, M. R., Hu, J., Wolsky, R. J., Watson, Z. L., Yamamoto, T. M., Costello, J. C., Clauset, A., Behbakht, K., Kumar, T. R., & Bitler, B. G. (2020). The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(23), 6362-6373. https://doi.org/10.1158/1078-0432.CCR-20-1762
Jordan, Kimberly R, et al. "The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,23 (2020): 6362-6373. doi: https://doi.org/10.1158/1078-0432.CCR-20-1762
Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 Dec 01;26(23):6362-6373. doi: 10.1158/1078-0432.CCR-20-1762. Epub 2020 Sep 14. PMID: 32928797; PMCID: PMC7923250.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries